Dabigatran
- Generic Name
- Dabigatran
- Brand Names
- Dabigatran Etexilate Leon Farma, Dabigatran Etexilate Accord, Pradaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N7O3
- CAS Number
- 211914-51-1
- Unique Ingredient Identifier
- I0VM4M70GC
- Background
Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.
The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42534
- Registration Number
- NCT03026556
- Locations
- 🇺🇸
Inventiv Health, Princeton, New Jersey, United States
Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease
Phase 4
Completed
- Conditions
- Atrial FibrillationValve Heart Disease
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT02982850
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT02945020
ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)
Phase 4
Completed
- Conditions
- Diabetes
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 300
- Registration Number
- NCT02935855
- Locations
- 🇮🇹
IRCCS Policlinico San Matteo, Pavia, Italy
Use of Public Health Surveillance Models in the French National Health System Database
Completed
- Conditions
- Atrial FibrillationAnticoagulantsPharmacoepidemiology
- Interventions
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Centre Hospitalier Universitaire de la Réunion
- Target Recruit Count
- 814446
- Registration Number
- NCT02904499
- Locations
- 🇫🇷
University Hospital of Reunion Island, Saint Denis, Reunion Island, France
The Coagulation Cascade in Idiopathic Pulmonary Fibrosis
Not Applicable
- Conditions
- Idiopathic Pulmonary FibrosisInterstitial Lung DiseaseIPF
- Interventions
- Radiation: FDG PET scan
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- University College, London
- Target Recruit Count
- 12
- Registration Number
- NCT02885961
Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD)
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- Daniel Zimpfer, MD
- Target Recruit Count
- 16
- Registration Number
- NCT02872649
- Locations
- 🇦🇹
Medical Univerity Vienna, Vienna, Austria
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 99999
- Registration Number
- NCT02864758
- Locations
- 🇫🇷
Many Locations, Multiple Locations, France
Direct Oral Anticoagulants and Venous Thromboembolism
Completed
- Conditions
- Major BleedVenous Thromboembolism
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
- Target Recruit Count
- 59525
- Registration Number
- NCT02833987
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 28000
- Registration Number
- NCT02792335
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath